TK PHARMA - Your health is our most valuable freight.

Rapid Medical's TIGERTRIEVER ™ Device Succeeds at First Attempt with Problematic Ischemic Stroke Patients With Intracranial Atherosclerotic Disease

Friday, November 17, 2023

Rapid Medical ™ , a leading developer of advanced neurovascular devices, announces new data demonstrating excellent first-pass treatment success with the TIGERTRIEVER ™ device in patients victims of complex ischemic stroke with underlying MAIC. Complication rates have been negligible, as announced at the 2023 Society of Vascular and Interventional Surgery (SVIN) Annual Meeting.

“MAIC patients with stroke are very difficult to treat and often require salvage treatment such as stenting,” said Dr. Edgar Samaniego , an endovascular neurologist at the University of Iowa and senior editor. . “We achieved very high rates of treatment effectiveness and long-lasting results with the TIGERTRIEVER device alone, which were not seen with other devices. We attribute this to the unique ability of the TIGERTRIEVER device to open and dilate these blocked vessels, a new term we call stentplasty. »

As published in the Journal of NeuroInterventional Surgery , this subanalysis of the prospective TIGER 1 trial showed that 78% of patients with MAIC received successful reperfusion without further intervention; 47% benefited from recanalization during the first pass. 2 These results are significantly better than studies using other devices in this unique patient population. In addition, the TIGERTRIEVER device used in a context of MAIC displays results similar to what was thought possible only in patients without MAIC. Another benefit of the high first pass success rates has been the very fast response times; the median time to revascularization of 22 minutes from the groin is the shortest ever published in any prospective randomized trial. Of note, 50% of these patients experienced a good clinical outcome, as defined by an mRS score of 0-2 at 90 days.

Unlike conventional stent retrievers, the TIGERTRIEVER device offers the unique ability to control radial expansion after placement in a cerebral artery, providing exclusive benefits to patients with MAIC. In addition to successful reperfusion, the TIGERTRIEVER allowed significant dilation of the artery, such that no patient required a permanent stent. Additionally, patients included in the study did not suffer from symptomatic intracranial hemorrhage, vascular dissection, or embolic complications – typically more common in these patients with MAIC – because the device can also be contracted to minimize disruption. plaque and arteries during removal.

“Practitioners now have a better, faster treatment option for patients with severely narrowed, stenotic arteries,” added Dr. Samaniego. “TIGERTRIEVER offers a higher rate of successful reperfusion, reduced complications and a desired angioplasty-like effect compared to historical studies that used other mechanical thrombectomy devices. »

For more information about the study, please refer to the article published in the Journal of NeuroInterventional Surgery:

About Rapid Medical

Rapid Medical is expanding the possibilities in neurovascular treatment by developing advanced interventional devices to treat ischemic and hemorrhagic strokes. Using proprietary manufacturing techniques, Rapid Medical's products are remotely adjustable and fully visible. This allows doctors to respond in real time to the anatomy and tailor the approach to each patient for better results from the procedures. TIGERTRIEVER ™ 13 , 17 and 21 , COMANECI ™ and COLUMBUS ™ /DRIVEWIRE carry the CE mark and are approved by the FDA. TIGERTRIEVER XL also benefits from CE marking. Further information is available at

1 Gupta R, Saver JL, Levy E, et al. New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial [a correction publication appears in Stroke. June 2021;52(6):e310]. Stroke . 2021;52(5):1534-1544. doi:10.1161/STROKEAHA.121.034436

2 Ojeda DJ, Ghannam M, Sanchez S, et al. Tigertriever in the treatment of acute ischemic stroke with underlying intracranial atherosclerotic disease [published online ahead of print, September 30, 2023]. J Neurointerv Surg . 2023;jnis-2023-020796. doi:10.1136/jnis-2023-020796

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation must always be compared with the source text, which will set a precedent.

Ronen Eckhouse